After a Year of Testing, Two Early PacBio Customers Expect More Routine Use of RS Sequencer in 2012 | GenomeWeb

By Julia Karow

A year after receiving the PacBio RS single-molecule sequencer in their labs, early-access customers from two research institutions have taken their instruments through their paces and are starting to analyze "real" samples.

As users at the Wellcome Trust Sanger Institute and the National Cancer Institute become more familiar with the type of data the instrument produces, they expect to apply their machines more routinely this year for projects that can benefit from long reads.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.